Key facts
- This page summarizes Mark James Litton's Form 4 filing for Athira Pharma, Inc. (ATHA).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 04 Mar 2025, 16:29.
Mark James Litton - 03 Mar 2025 Form 4 Insider Report for Athira Pharma, Inc. (ATHA)
- Reporting relationship
- President and CEO, Director
- Issuer ticker
- ATHA
- Reported as of
- 03 Mar 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 04 Mar 2025, 16:29:47 UTC
- Prior SEC filing
- 03 Jan 2025
- Next SEC filing
- 02 Jul 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mark Worthington, Attorney-in-Fact for Mark James Litton
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Mark James Litton filed Form 4 for Athira Pharma, Inc. (ATHA) on 04 Mar 2025.
Change
- Previous filing in this sequence was filed on 03 Jan 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ATHA
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +333,815
- Change %
- Price
- $0.000000
- Shares after
- 333,815
- Date
- 03 Mar 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 333,815
- Exercise price
- $0.3762
- Footnotes
- F1
ATHA
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +222,543
- Change %
- Price
- $0.000000
- Shares after
- 222,543
- Date
- 03 Mar 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 222,543
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The shares subject to the option shall be scheduled to vest monthly over a term of 48 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan) through the applicable vesting dates.
Footnote F2
Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of Issuer's common stock.
Footnote F3
100% of the RSUs shall vest on the one (1) year anniversary of the grant date, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan (the "Plan")) through the vesting date.